症例から学ぶ　がん患者の感染症入門

出版社： 中外医学社
著者：
発行日： 2021-04-10
分野： 臨床医学：一般  >  癌/腫瘍一般
ISBN： 9784498021365
電子書籍版： 2021-04-10 （1版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

4,840 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

4,840 円(税込)

購入する

商品紹介

がん患者さんの発熱と聞くとため息が出てしまう．そんな先生も多いのではないでしょうか？（本書に登場するDr.古谷もそうだったとか．）そんな悩みは本書で解決！　診療機会の多い固形腫瘍にフォーカスし，基本事項を踏まえつつ，複雑な問題をロジカルかつ華麗に解説します．Dr.伊東×Dr.古谷のコントさながらのやり取りを楽しく読むだけで，がん患者の感染症が得意になること間違いなしです．

目次

  • CHAPTER  1 　がん患者の感染症総論
    　1　はじめに
    　2　救急を受診するがん患者の症状と原因
    　3　日本における固形腫瘍と血液悪性腫瘍の疫学
    　4　固形腫瘍患者の感染症
    　5　固形腫瘍患者における感染症のロジック
    　6　おわりに
    Memo 　カテーテル関連血流感染症の診断
    Mini Lecture 　リンパ囊胞感染
    　1　リンパ囊胞とは
    　2　リンパ囊胞感染
    　3　リンパ囊胞感染の原因微生物
    　4　リンパ囊胞感染の治療
    Mini Lecture 　免疫抑制・化学療法により発症するB型肝炎対策

    CHAPTER  2 　発熱性好中球減少症のマネージメント
    　1　はじめに
    　2　発熱性好中球減少症とは
    　3　発熱性好中球減少症の疫学・リスク因子
    　4　発熱性好中球減少症の臨床的特徴
    　5　発熱性好中球減少症の原因と微生物
    　6　発熱性好中球減少症のリスク分類
    　7　発熱性好中球減少症の初期対応
    　8　発熱性好中球減少症の治療期間
    　9　FNで広域抗菌薬開始後原因不明の発熱が3～4日続く時
    　10　低リスク症例の外来治療
    Mini Lecture 　D-index
    Mini Lecture 　好中球減少時のG-CSF投与
    　1　G-CSFの一次的予防投与
    　2　G-CSFの二次的予防投与
    　3　G-CSFの治療的投与

    CHAPTER  3 　液性免疫不全を認識せよ！
    　1　はじめに
    　2　液性免疫不全とは
    　3　液性免疫不全に関連する微生物
    　4　脾機能の評価法
    　5　脾臓摘出後重症感染症とは
    　6　OPSIの予防のために
    　7　患者教育について
    Colum 　血液培養の偽陽性

    CHAPTER  4 　細胞性免疫不全を考える
    　1　はじめに
    　2　症例検討1
    　3　細胞性免疫不全とは
    　4　細胞性免疫不全に関連する微生物
    　5　細胞性免疫不全とびまん性すりガラス陰影
    　6　ニューモシスチス肺炎を疑った際の検査
    　7　症例検討1の経過
    　8　症例検討2
    　9　多発性骨髄腫とその治療薬
    　10　症例検討2のつづき
    　11　症例検討3
    Mini Lecture 　播種性帯状疱疹
    Mini Lecture 　ニューモシスチス肺炎
    　1　ニューモシスチス肺炎とは
    　2　診断のポイント
    　3　鑑別診断
    Mini Lecture 　サイトメガロウイルス肺炎
    　1　サイトメガロウイルス肺炎の特徴
    　2　サイトメガロウイルス肺炎の診断
    　3　サイトメガロウイルス肺炎の治療
    Mini Lecture 　粟粒結核
    　1　粟粒結核とは？
    　2　疫学
    　3　基礎疾患・リスク因子
    　4　臨床症状
    　5　診断アプローチ
    　6　検査所見
    　7　治療

    CHAPTER  5 　バリア障害
    　1　はじめに
    　2　皮膚のバリア障害
    　3　粘膜のバリア障害
    　4　おわりに
    Mini Lecture 　中心静脈カテーテル関連血流感染症の治療
    　1　治療のポイント
    　2　至適治療期間
    　3　治療に伴う問題点?　黄色ブドウ球菌が原因の場合の治療期間
    　4　治療に伴う問題点?　黄色ブドウ球菌が原因の場合の内服変更

    CHAPTER  6 　構造異常
    　1　管腔の閉塞による感染症
    　2　瘻孔形成による感染症
    　3　手術による解剖学的変化に伴う感染症
    　4　おわりに
    Mini Lecture 　リンパ浮腫における蜂窩織炎
    　1　がん治療とリンパ浮腫
    　2　リンパ浮腫における蜂窩織炎
    　3　リンパ浮腫における蜂窩織炎の原因微生物
    　4　リンパ浮腫における蜂窩織炎の治療
    　5　抗菌薬の予防内服について

    CHAPTER  7 　がん患者とワクチン
    　1　はじめに
    　2　がん患者とインフルエンザワクチン
    　3　がん患者のインフルエンザワクチンの有効性
    　4　インフルエンザワクチン接種の安全性
    　5　インフルエンザワクチンの接種時期
    　6　外科手術前のインフルエンザワクチンの接種時期
    　7　肺炎球菌ワクチン

    CHAPTER  8 　がんを模倣する感染症
    　1　はじめに
    　2　肺がん疑いで紹介受診する患者の最終診断
    　3　結核の疑いがあれば空気感染対策を行う
    　4　おわりに
    Colum 　寄生虫とがん
    Mini Lecture 　がんを示唆する微生物
    　1　Streptococcus gallolyticus subspecies gallolyticus
    　2　Aeromonas caviae
    　3　Clostridium septicum

    CHAPTER  9 　手術と感染症
    　1　はじめに
    　2　術後の発熱とは
    　3　術後患者の発熱の原因と診断アプローチ
    　4　時期別にみた発熱のアプローチ
    　5　おわりに
    Mini Lecture 　腹腔内感染症の治療
    　1　はじめに
    　2　国内・国外のガイドライン
    　3　どういった微生物をカバーするのか
    　4　1　軽症〜中等症の市中感染症で想定すべき微生物と経験的治療
    　4　2　重症市中感染症あるいは医療関連感染症で想定すべき微生物と経験的治療
    　4　3　腸球菌，カンジダ，MRSAの治療オプション
    　5　治療期間はどうするのか

    CHAPTER  10 　腫瘍熱
    　1　はじめに
    　2　腫瘍熱の疫学
    　3　腫瘍熱の定義
    　4　腫瘍熱のメカニズム
    　5　腫瘍熱におけるバイオマーカー
    　6　腫瘍熱診断のアルゴリズム
    　7　ナプロキセンテスト
    　8　おわりに
    Mini Lecture 　がん患者と薬剤熱
    　1　はじめに
    　2　薬剤熱の定義
    　3　薬剤熱の発症機序
    　4　薬剤熱の症状
    　5　がん患者において薬剤熱を起こしやすい薬剤は？

    CHAPTER  11 　新規がん薬物療法と感染症
    　1　はじめに
    　2　免疫関連有害事象とは？
    　3　免疫チェックポイント阻害薬使用中の下痢
    　4　VEGF阻害薬/ VEGF受容体阻害薬
    Colum 　感染症治療中の化学療法
    Mini Lecture 　膀胱内BCG注入療法後のBCG感染症
    　1　BCGと膀胱がんに対する膀胱内BCG注入療法
    　2　膀胱内BCG注入療法の合併症
    　3　いつBCG感染症を疑うか
    　4　BCG感染症の診断アプローチ
    　5　BCG感染症の治療法

    CHAPTER  12 　放射線治療と感染症
    　1　はじめに
    　2　放射線による急性反応と晩期反応
    　3　化学放射線療法による急性細菌性耳下腺炎
    　4　放射線治療による嚥下機能障害
    　5　放射線治療による遅発性縫合不全
    Mini Lecture 　誤嚥性肺臓炎と誤嚥性肺炎
    　1　誤嚥性肺臓炎と誤嚥性肺炎は違う
    　2　誤嚥性肺炎の起因菌として嫌気性菌が検出される割合は低い

    CHAPTER  13 　終末期のがん患者と感染症
    　1　はじめに
    　2　終末期がん患者の特徴
    　3　終末期がん患者の感染症部位・微生物・抗菌薬治療
    　4　終末期がん患者の感染症診断
    　5　終末期がん患者に抗菌薬は使用すべきか
    　6　終末期がん患者における抗菌薬使用の決定
    　7　おわりに

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

[CHAPTER 1] がん患者の感染症総論

P.12 掲載の参考文献
1) Tanriverdi O, Beydilli H, Yildirim B, et al. Single center experience on causes of cancer patients visiting the emergency department in southwest Turkey. Asian Pac J Cancer Prev. 2014 ; 15 : 687-90.
PubMed
2) Ahn S, Lee YS, Lim KS, et al. Emergency department cancer unit and management of oncologic emergencies : experience in Asan Medical Center. Support Care Cancer. 2012 ; 20 : 2205-10.
PubMed
3) Rolston KV. Infections in cancer patients with solid tumors : a review. Infect Dis Ther. 2017 ; 6 : 69-83.
PubMed
4) 公益財団法人がん研究振興財団. がんの統計 '17 https://ganjoho.jp/reg_stat/statistics/brochure/backnumber/2017_jp.html (Accessed 2018/12/15)
 
5) Kawamura I, Hirashima Y, Tsukahara M, et al. Microbiology of pelvic lymphocyst infection after lymphadenectomy for malignant gynecologic tumors. Surg Infect (Larchmt). 2015 ; 16 : 244-6.
PubMed
6) 倉井華子, 冲中敬二, 岸田直樹, 他編. がん患者の感染症診療マニュアル. 改訂2版. 東京 : 南山堂 ; 2012.
 
7) 伊東直哉. 感染症内科ただいま診断中!. 東京 : 中外医学社 ; 2017.
 
8) Marin M, Gudiol C, Garcia-Vidal C, et al. Bloodstream infections in patients with solid tumors : epidemiology, antibiotic therapy, and outcomes in 528 episodes in a single cancer center. Medicine (Baltimore). 2014 ; 93 : 143-9.
 
9) Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection : 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009 ; 49 : 1-45.
 
10) 福井次矢, 黒川清 (日本語版監修). ハリソン内科学. 第5版. 東京 : メディカル・サイエンス・インターナショナル ; 2017.
 
11) Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989 ; 11 : 954-963.
PubMed
P.14 掲載の参考文献
1) Ma X, Wang Y, Fan A, et al. Risk factors, microbiology and management of infected lymphocyst after lymphadenectomy for gynecologic malignancies. Arch Gynecol Obstet. 2018 ; 298 (6) : 1195-203.
PubMed
2) Ferguson JH, Maclure JG. Lymphocele following lymphadenectomy. Am J Obstet Gynecol. 1961 ; 82 : 783-92.
PubMed
3) Weinberger V, Cibula D, Zikan M. Lymphocele : prevalence and management in gynecological malignancies. Expert Rev Anticancer Ther. 2014 ; 14 : 307-17.
PubMed
4) Kawamura I, Hirashima Y, Tsukahara M, et al. Microbiology of pelvic lymphocyst infection after lymphadenectomy for malignant gynecologic tumors. Surg Infect (Larchmt). 2015 ; 16 : 244-46.
PubMed
5) Hiramatsu K, Kobayashi E, Ueda Y, et al. Optimal timing for drainage of infected lymphocysts after lymphadenectomy for gynecologic cancer. Int J Gynecol Cancer. 2015 ; 25 : 337-41.
PubMed
6) Nogami Y, Banno K, Adachi M, et al. Profiling of the causative bacteria in infected lymphocysts after lymphadenectomy for gynecologic cancer by pyrosequencing the 16s ribosomal RNA gene using next-generation sequencing technology. Infect Dis Obstet Gynecol. 2019 ; 2019 : 9326285.
PubMed
P.16 掲載の参考文献
1) 日本肝臓学会. B型肝炎治療ガイドライン https://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_b
 

[CHAPTER 2] 発熱性好中球減少症のマネージメント

P.35 掲載の参考文献
1) Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966 ; 64 : 328-40.
PubMed
2) Freifeld AG, Bow EJ, Sepkowitz KA, et al. Infectious Diseases Society of America clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer : 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011 ; 52 : 427-31.
 
3) 日本臨床腫瘍学会. 発熱性好中球減少症 (FN) 診療ガイドライン. 東京 : 南江堂 ; 2012.
 
4) Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression : ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018 [epub ahead of print].
 
5) Bodey GP. Unusual presentations of infection in neutropenic patients. Int J Antimicrob Agents. 2000 ; 16 : 93-5.
PubMed
6) Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med. 1975 ; 135 : 715-9.
PubMed
7) Nesher L, Rolston KV. The current spectrum of infection in cancer patients with chemotherapy related neutropenia. Infection. 2014 ; 42 : 5-13.
PubMed
8) Safdar A (editor). Principles and practice of cancer infectious diseases. New York : Humana Press ; 2011.
 
9) Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol. 2010 ; 36 : 1-53.
PubMed
10) Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy : American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. J Clin Oncol. 2018 ; 36 : 1443-53.
 
11) Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy : American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013 ; 31 : 794-810.
 
12) NCCN guidelines ver. 2. 2020 Prevention and Treatment of Cancer-Related Infections. https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf (Accessed 2020/8/31)
 
13) Paul M, Dickstein Y, Schlesinger A, et al. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. Cochrane Database Syst Rev. 2013 ; 6 : CD003038.
PubMed
14) Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance : summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 2013 ; 98 : 1826-35.
PubMed
15) Schmidt-Hieber M, Teschner D, Maschmeyer G, et al. Management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuation. Expert Rev Anti Infect Ther. 2019 ; 17 : 983-95.
PubMed
16) Paul M, Dickstein Y, Borok S, et al. Empirical antibiotics targeting gram-positive bacteria for the treatment of febrile neutropenic patients with cancer. Cochrane Database Syst Rev. 2014 ; 1 : CD003914.
PubMed
P.38 掲載の参考文献
1) Cornillet A, Camus C, Nimubona S, et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients : A 6-year survey. Clin Infect Dis. 2006 ; 43 : 577-84.
PubMed
2) Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients : Changes in epidemiology and risk factors. Blood. 2002 ; 100 : 4358-66.
PubMed
3) Nucci M, Anaissie EJ, Queiroz-Telles F, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer. 2003 ; 98 : 315-319.
PubMed
4) Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies : The SEIFEM-2004 study. Haematologica. 2006 ; 91 : 1068-75.
 
5) Portugal RD, Garnica M, Nucci M. Index to predict invasive mold infection in highrisk neutropenic patients based on the area over the neutrophil curve. J Clin Oncol. 2009 ; 27 : 3849-54.
 
6) Kimura S, Oshima K, Sato K, et al. Retrospective evaluation of the area over the neutrophil curve index to predict early infection in hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2010 ; 16 : 1355-61.
PubMed
P.43 掲載の参考文献
1) Freifeld AG, Bow EJ, Sepkowitz KA, et al. Infectious Diseases Society of America clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer : 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011 ; 52 : 427-31.
 
2) NCCN guidelines ver. 2. 2020 Hematopoietic Growth Factors. https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf (Accessed 2020/8/31)
 
3) NCCN guidelines ver. 2. 2020 Prevention and Treatment of Cancer-Related Infections. https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf (Accessed 2020/8/31)
 
4) Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the Use of WBC Growth Factors : American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015 ; 33 : 3199-212.
 
5) 日本癌治療学会. G-CSF適正使用診療ガイドライン. http://www.jsco-cpg.jp/guideline/30.html
 
6) Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy : a meta-analysis. Am J Med. 2002 ; 112 : 406-11.
PubMed
7) Bohlius J, Herbst C, Reiser M, et al. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma (Review). Cochrane Database Syst Rev. 2008 ; 8 : CD003189.
 
8) Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy : a systematic review. J Clin Oncol. 2007 ; 25 : 3158-67.
PubMed
9) Sung L, Nathan PC, Alibhai SM, et al. Meta-analysis : effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 2007 ; 147 : 400-11.
PubMed
10) Cooper KL, Madan J, Whyte S, et al. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy : systematic review and meta-analysis. BMC Cancer. 2011 ; 11 : 404.
PubMed
11) Lyman GH, Dale DC, Culakova E, et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival : a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2013 ; 24 : 2475-84.
PubMed
12) Haim N, Shulman K, Goldberg H, et al. The safety of full-dose chemotherapy with secondary prophylactic granulocyte colony stimulating factor (G-CSF) following a prior cycle with febrile neutropenia. Med Oncol. 2005 ; 22 : 229-32.
PubMed
13) Gupta S, Singh PK, Bhatt ML, et al. Efficacy of granulocyte colony stimulating factor as a secondary prophylaxis along with full-dose chemotherapy following a prior cycle of febrile neutropenia. Biosci Trends. 2010 ; 4 : 273-8.
PubMed
14) Mhaskar R, Clark OA, Lyman G, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev. 2014 ; 2014 (10) : CD003039. Published 2014 Oct 30.
 

[CHAPTER 3] 液性免疫不全を認識せよ !

P.55 掲載の参考文献
1) Safdar A (editor). Principles and practice of cancer infectious diseases. New York : Humana Press ; 2011.
 
2) Di Sabatino A, Carsetti R, Corazza GR. Post-splenectomy and hyposplenic states. Lancet. 2011 ; 378 : 86-97.
PubMed
3) Rubin LG, Schaffner W. Clinical practice. Care of the asplenic patient. N Engl J Med. 2014 ; 371 : 349-56.
 
4) Rossi P, Oger A, Bagneres D, et al. Capnocytophaga canimorsus septicaemia in an asplenic patient with systemic lupus erythematosus. BMJ Case Rep. 2009 ; pii : 1840.
 
5) de Porto AP, Lammers AJ, Bennink RJ, et al. Assessment of splenic function. Eur J Clin Microbiol Infect Dis. 2010 ; 29 : 1465-73.
PubMed
6) Holdsworth RJ, Irving AD, Cuschieri A. Postsplenectomy sepsis and its mortality rate : actual versus perceived risks. Br J Surg. 1991 ; 78 : 1031-8.
PubMed
7) Davidson RN, Wall RA. Prevention and management of infections in patients without a spleen. Clin Microbiol Infect. 2001 ; 7 : 657-60.
PubMed
8) Rubin LG, Levin MJ, Ljungman P, et al. Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014 ; 58 : 309-18.
 
9) Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions : recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012 ; 61 : 816-9.
PubMed
10) Briere EC, Rubin L, Moro PL, et al. Division of bacterial diseases, National Center for Immunization and Respiratory Diseases, CDC. Prevention and control of haemophilus influenzae type b disease : Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014 ; 63 : 1-14.
PubMed
11) Cohn AC, MacNeil JR, Clark TA, et al. Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease : recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013 ; 62 : 1-28.
PubMed
12) 佐々木裕子, 増田まり子, 久保田眞由美, 他. 小児の侵襲性感染症患者から分離されたHaemophilus influenzaeの莢膜型別解析について : 国内外の動向. IASR. 2014 ; 35 : 231-2.
 
13) 国立感染症研究所. 侵襲性髄膜炎菌感染症 2013年4月～2017年10月. IASR. 2018 ; 39 : 1-2.
 
14) Tartof SY, Gounder P, Weiss D, et al. Bordetella holmesii bacteremia cases in the United States, April 2010-January 2011. Clin Infect Dis 2014 ; 58 : e39.
PubMed
15) Pittet LF, Posfay-Barbe KM. Bordetella holmesii : Still Emerging and Elusive 20 Years On. Microbiol Spectr. 2016 ; 4 (2).
 
16) Mir-Cros A, Codina G, Martin-Gomez MT, et al. Emergence of Bordetella holmesii as a Causative Agent of Whooping Cough, Barcelona, Spain. Emerg Infect Dis 2017 ; 23 : 1856.
 
17) Fong W, Timms V, Holmes N, et al. Detection and incidence of Bordetella holmesii in respiratory specimens from patients with pertussis-like symptoms in New South Wales, Australia. Pathology 2018 ; 50 : 322.
PubMed
18) Zahid MF, Bains APS. Rapidly fatal Klebsiella pneumoniaesepsis in a patient with pyruvate kinase deficiency and asplenia. Blood 2017 ; 130 : 2906.
 
P.57 掲載の参考文献
1) Reimer LG, Wilson ML, Weinstein MP. Update on detection of bacteremia and fungemia. Clin Microbiol Rev. 1997 ; 10 (3) : 444-65. doi : 10.1128/CMR.10.3.444-465.1997.
 
2) Ziegler R, Johnscher I, Martus P, et al. Controlled clinical laboratory comparison of two supplemented aerobic and anaerobic media used in automated blood culture systems to detect bloodstream infections. J Clin Microbiol. 1998 ; 36 : 657-61.
PubMed
3) Ebihara Y, Kobayashi K, Watanabe N, et al. False-positive blood culture results in patients with hematologic malignancies. J Infect Chemother. 2019 ; 25 (5) : 404-6.
PubMed
4) Khan M, Siddiqi R, Konopleva M, et al. Increased peripheral leukemia blasts leading to false-positive blood culture. Blood Cells Mol Dis. 2017 ; 64 : 8-9.
PubMed
5) Turan DR, Kuruoglu T, Gumus D, et al. Evaluation of factors that may cause false positive growth signals in blood cultures-as the word 'Factors' will include both microbial and patients as well as others. Int J Clin Med Microbiol. 2018 : 3 : 137.
 
6) Ruiz-Giardin JM, Martin-Diaz RM, Jaqueti-Aroca J, et al. Diagnosis of bacteraemia and growth times. Int J Infect Dis. 2015 ; 41 : 6-10.
PubMed

[CHAPTER 4] 細胞性免疫不全を考える

P.76 掲載の参考文献
1) Bennett JE, et al. Principles and Practice of Infectious Diseases, 8th ed, Elsevier, 2015.
 
2) Safdar A. Principles and Practice of Cancer Infectious Diseases. Humana Press, 2011.
 
3) Worth LJ, Dooley MJ, Seymour JF, et al. An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital. Br J Cancer. 2005 ; 92 (5) : 867-72.
 
4) Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989 ; 11 : 954-63.
PubMed
5) Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression : ASCOand IDSA Clinical Practice Guideline Update. J Clin Oncol. 2018 ; 36 : 3043-54.
PubMed
6) Lundin J, Porwit-MacDonald A, Rossmann ED, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia. 2004 ; 18 : 484-90.
PubMed
7) Grossman SA, Ye X, Lesser G, Sloan A, et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res. 2011 ; 17 : 5473-80.
PubMed
8) Neumann S, Krause SW, Maschmeyer G, et al. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2013 ; 92 : 433-42.
PubMed
9) Baulier G, Issa N, Gabriel F, et al. Guidelines for prophylaxis of Pneumocystis pneumonia cannot rely solely on CD4-cell count in autoimmune and inflammatory diseases. Clin Exp Rheumatol. 2018 ; 36 : 490-93.
PubMed
10) Sonneville R, Magalhaes E, Meyfroidt G. Central nervous system infections in immunocompromised patients. Curr Opin Crit Care. 2017 ; 23 : 128-133.
PubMed
11) Schmidt-Hieber M, Zweigner J, Uharek L, et al. Central nervous system infections in immunocompromised patients : update on diagnostics and therapy. Leuk Lymphoma. 2009 ; 50 : 24-36.
PubMed
12) Lopez FA, Sanders CV. Dermatologic infections in the immunocompromised (non-HIV) host. Infect Dis Clin North Am. 2001 ; 15 : 671-702, xi.
 
13) Wolfson JS, Sober AJ, Rubin RH. Dermatologic manifestations of infections in immunocompromised patients. Medicine (Baltimore). 1985 ; 64 : 115-33.
PubMed
14) Franquet T. High-resolution computed tomography (HRCT) of lung infections in non-AIDS immunocompromised patients. Eur Radiol. 2006 ; 16 : 707-18.
PubMed
15) Oh YW, Effmann EL, Godwin JD. Pulmonary infections in immunocompromised hosts : the importance of correlating the conventional radiologic appearance with the clinical setting. Radiology. 2000 ; 217 : 647-56.
PubMed
16) Ainoda Y, Hirai Y, Fujita T, et al. Analysis of clinical features of non-HIV Pneumocystis jirovecii pneumonia. J Infect Chemother. 2012 ; 18 : 722-8.
PubMed
17) Azoulay E, Bergeron A, Chevret S, et al. Polymerase chain reaction for diagnosing pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates. Chest. 2009 ; 135 : 655-61.
PubMed
18) Fujisawa T, Suda T, Matsuda H, et al. Real-time PCR is more specific than conventional PCR for induced sputum diagnosis of Pneumocystis pneumonia in immunocompromised patients without HIV infection. Respirology. 2009 ; 14 : 203-9.
PubMed
19) Watanabe T, Yasuoka A, Tanuma J, et al. Serum (1-->3) beta-D-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. Clin Infect Dis. 2009 ; 49 : 1128-31.
 
20) Tasaka S, Hasegawa N, Kobayashi S, et al. Serum indicators for the diagnosis of pneumocystis pneumonia. Chest. 2007 ; 131 : 1173-80.
 
21) Fischer S, Gill VJ, Kovacs J, et al. The use of oral washes to diagnose Pneumocystis carinii pneumonia : a blinded prospective study using a polymerase chain reaction-based detection system. J Infect Dis. 2001 ; 184 : 1485-8.
PubMed
22) Matsumura Y, Ito Y, Iinuma Y, et al. Quantitative real-time PCR and the (1→3) -β-D-glucan assay for differentiation between Pneumocystis jirovecii pneumonia and colonization. Clin Microbiol Infect. 2012 ; 18 : 591-7.
 
23) Wieruszewski PM, Barreto JN, Frazee E, et al. Early corticosteroids for Pneumocystis pneumonia in adults without hiv are not associated with better outcome. Chest. 2018 ; 154 : 636-44.
 
24) Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis. 2009 ; 49 : 1211-25.
PubMed
25) Gafter-Gvili A, Polliack A. Bendamustine associated immune suppression and infections during therapy of hematological malignancies. Leuk Lymphoma. 2016 ; 57 (3) : 512-519. doi:10.3109/10428194.2015.1110748
 
26) Saito H, Maruyama D, Maeshima AM, et al. Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and Mantle cell lymphoma [published correction appears in Blood Cancer J. 2017 Nov 3 ; 7 (11) : e620]. Blood Cancer J. 2015 ; 5 (10) : e362.
 
27) Neuber B, Dai J, Waraich WA, et al. Lenalidomide overcomes the immunosuppression of regulatory CD8+ CD28- T-cells. Oncotarget. 2017 ; 8 : 98200-98214. Published 2017 Oct 5.
 
28) Zonder JA, Crowley J, Hussein MA, et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma : a randomized Southwest Oncology Group trial (S0232). Blood. 2010 ; 116 : 5838-5841.
 
29) Groen K, van de Donk N, Stege C, et al. Carfilzomib for relapsed and refractory multiple myeloma. Cancer Manag Res. 2019 ; 11 : 2663-75.
PubMed
30) Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004 ; 39 : 1267-84. Epub 2004 Oct 6.
 
31) Thonnings S, Knudsen JD, Schonheyder HC, et al. Antibiotic treatment and mortality in patients with Listeria monocytogenes meningitis or bacteraemia. Clin Microbiol Infect. 2016 ; 22 : 725-30.
PubMed
P.80 掲載の参考文献
1) Cohen JI. Clinical practice : Herpes zoster. N Engl J Med. 2013 ; 369 : 255-63.
PubMed
2) CDC. Shingles (Herpes Zoster). https://www.cdc.gov/shingles/hcp/clinical-overview.html
PubMed
3) CDC. yellow book. Immunocompromised Travelers. https://wwwnc.cdc.gov/travel/yellowbook/2020/travelers-with-additionalconsiderations/immunocompromised-travelers?fbclid=IwAR3xUBLx57bXsEejNqwBUzfQZhYXvlIR1jcdSeHtVSWknDyfNtiEE40WWuk
 
4) Rubin LG, Levin MJ, Ljungman P, et al. Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014 ; 58 : 309-18.
 
5) CDC. Interim Infection Prevention and Control Recommendations for Measles in Healthcare Settings. https://www.cdc.gov/infectioncontrol/guidelines/measles/index.html#appendixA
 
6) CDC. Red Book. http://redbook.solutions.aap.org/redbook.aspx
 
7) Preventing Varicella-Zoster Virus (VZV) Transmission from Herpes Zoster in Healthcare Settings https://www.cdc.gov/shingles/hcp/hc-settings.html#patients
 
P.83 掲載の参考文献
1) Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis. 2002 ; 8 : 891-6.
PubMed
2) Sepkowitz KA, Brown AE, Telzak EE, et al. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA. 1992 ; 267 : 832-7.
 
3) Barbounis V, Aperis G, Gambletsas E, et al. Pneumocystis carinii pneumonia in patients with solid tumors and lymphomas : predisposing factors and outcome. Anticancer Res. 2005 ; 25 : 651-5.
PubMed
4) Catherinot E, Lanternier F, Bougnoux ME, et al. Pneumocystis jirovecii Pneumonia. Infect Dis Clin North Am. 2010 ; 24 : 107-38.
PubMed
5) El Ghoul R, Eckardt SM, Mukhopadhyay S, et al. Fever and dyspnea in a 61-yearold woman with metastatic breast cancer. Chest. 2009 ; 136 : 634-8.
 
6) Tasaka S, Tokuda H. Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies. J Infect Chemother. 2012 ; 18 : 793-806.
PubMed
7) Miller WT Jr, Shah RM. Isolated diffuse ground-glass opacity in thoracic CT : causes and clinical presentations. AJR Am J Roentgenol. 2005 ; 184 : 613-22.
PubMed
8) Hewitt MG, Miller WT Jr, Reilly TJ, et al. The relative frequencies of causes of widespread ground-glass opacity : a retrospective cohort. Eur J Radiol. 2014 ; 83 : 1970-6.
PubMed
P.85 掲載の参考文献
1) Salomon N, Gomez T, Perlman DC, et al. Clinical features and outcomes of HIV-related cytomegalovirus pneumonia. AIDS. 1997 ; 11 : 319-24.
PubMed
2) Cascio A, Iaria C, Ruggeri P, et al. Cytomegalovirus pneumonia in patients with inflammatory bowel disease : a systematic review. Int J Infect Dis. 2012 ; 16 : e474-e9.
PubMed
3) Moon JH, Kim EA, Lee KS, et al. Cytomegalovirus pneumonia : high-resolution CT findings in ten non-AIDS immunocompromised patients. Korean J Radiol. 2000 ; 1 : 73-8.
PubMed
4) Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002 ; 34 : 1094-7.
PubMed
5) Crawford SW, Bowden RA, Hackman RC, et al. Rapid detection of cytomegalovirus pulmonary infection by bronchoalveolar lavage and centrifugation culture. Ann Intern Med. 1988 ; 108 : 180-5.
PubMed
6) Cathomas G, Morris P, Pekle K, et al. Rapid diagnosis of cytomegalovirus pneumonia in marrow transplant recipients by bronchoalveolar lavage using the polymerase chain reaction, virus culture, and the direct immunostaining of alveolar cells. Blood. 1993 ; 81 : 1909-14.
PubMed
7) Bek B, Boeckh M, Lepenies J, et al. High-level sensitivity of quantitative pp65 cytomegalovirus (CMV) antigenemia assay for diagnosis of CMV disease in AIDS patients and follow-up [published correction appears in J Clin Microbiol 1996 May ; 34 (5) : 1350]. J Clin Microbiol. 1996 ; 34 : 457-9.
 
8) van den Berg AP, Klompmaker IJ, Haagsma EB, et al. Antigenemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation. J Infect Dis. 1991 ; 164 : 265-70.
PubMed
9) van den Berg AP, van der Bij W, van Son WJ, et al. Cytomegalovirus antigenemia as a useful marker of symptomatic cytomegalovirus infection after renal transplantation--a report of 130 consecutive patients. Transplantation. 1989 ; 48 : 991-5.
PubMed
10) Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients- Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019 ; 33 : e13512.
PubMed
P.90 掲載の参考文献
1) Sharma SK, Mohan A. Miliary Tuberculosis. Microbiol Spectr. 2017 ; 5 : 10.
 
2) Tuddenham WJ. Glossary of terms for thoracic radiology : recommendations of the Nomenclature Committee of the Fleischner Society. AJR Am J Roentgenol. 1984 ; 143 : 509-17.
PubMed
3) Sharma SK, Mohan A. Tuberculosis : From an incurable scourge to a curable disease-journey over a millennium. Indian J Med Res. 2013 ; 137 : 455-93.
 
4) Sharma SK, Mohan A. Extrapulmonary tuberculosis. Indian J Med Res. 2004 ; 120 : 316-53.
PubMed
5) Sharma SK, Mohan A, Kadhiravan T. HIV-TB co-infection : epidemiology, diagnosis & management. Indian J Med Res. 2005 ; 121 : 550-67.
PubMed
6) https://www.cdc.gov/tb/statistics/
PubMed
7) 結核. 2016年現在. IASR Vol. 38 p231-232 : 2017年12月号 https://www.niid.go.jp/niid/ja/tuberculosis-m/tuberculosis-iasrtpc/7725-454t.html
 
8) Cunha BA, Krakakis J, McDermott BP. Fever of unknown origin (FUO) caused by miliary tuberculosis : diagnostic significance of morning temperature spikes. Heart Lung. 2009 ; 38 : 77-82.
PubMed

[CHAPTER 5] バリア障害

P.101 掲載の参考文献
1) Rolston KV. Infections in cancer patients with solid tumors : a review. Infect Dis Ther. 2017 ; 6 : 69-83.
PubMed
2) Safdar N, Maki DG. Inflammation at the insertion site is not predictive of catheter-related bloodstream infection with short-term, noncuffed central venous catheters. Crit Care Med. 2002 ; 30 : 2632-5.
PubMed
3) Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals : analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004 ; 39 : 309-17.
PubMed
4) Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection : 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009 ; 49 : 1-45.
 
5) Murdoch DR, Greenlees RL. Rapid identification of Staphylococcus aureus from BacT/ALERT blood culture bottles by direct Gram stain characteristics. J Clin Pathol. 2004 ; 57 : 199-201.
PubMed
6) Kondo S, Yamada T, Misawa S, et al. Morphological identification of Staphylococcus spp. from blood culture bottles based on direct Gram staining. Kansenshogaku Zasshi. 2008 ; 82 : 656-7.
PubMed
7) Safdar A. Principles and practice of cancer infectious diseases. New Jersey : Humana Press ; 2011.
 
8) Rolston KV, Mihu C, Tarrand JJ. Current microbiology of percutaneous endoscopic gastrostomy tube (PEG tube) insertion siteinfections in patients with cancer. Support Care Cancer. 2011 ; 19 : 1267-71.
 
9) Sato A, Nakamura I, Fujita H, et al. Peripheral venous catheter-related bloodstream infection is associated with severe complications and potential death : a retrospective observational study. BMC Infect Dis. 2017 ; 17 : 434.
 
10) Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer : 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011 ; 52 : 427-31.
 
11) Radocha J, Paterova P, Zavrelova A, et al. Viridans group streptococci blood-stream infections in neutropenic adult patients with hematologic malignancy : single center experience. Folia Microbiol (Praha). 2018 ; 63 : 141-6. 11.
 
12) Hadano Y, Isoda M, Ishibashi K, et al. Validation of blood culture gram staining for the detection of Staphylococcus aureus by the 'oozing sign' surrounding clustered gram-positive cocci : a prospective observational study. BMC Infect Dis. 2018 ; 18 : 490.
 
P.105 掲載の参考文献
1) Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection : 2009 Update by the Infectious Diseases Society of America [published correction appears in Clin Infect Dis. 2010 ; 50 : 1079. Dosage error in article text] [published correction appears in Clin Infect Dis. 2010 ; 50 : 457]. Clin Infect Dis. 2009 ; 49 : 1-45.
 
2) Dugdale DC, Ramsey PG. Staphylococcus aureus bacteremia in patients with Hickman catheters. Am J Med. 1990 ; 89 : 137-41.
PubMed
3) Nguyen MH, Peacock JE Jr, Tanner DC, et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med. 1995 ; 155 : 2429-35.
 
4) Raad I, Chaftari AM, Zakhour R, et al. Successful salvage of central venous catheters in patients with catheter-related or central line-associated bloodstream infections by using a catheter lock solution consisting of minocycline, EDTA, and 25% ethanol. Antimicrob Agents Chemother. 2016 ; 60 : 3426-32.
PubMed
5) Rijnders BJ, Van Wijngaerden E, Vandecasteele SJ, et al. Treatment of long-term intravascular catheter-related bacteraemia with antibiotic lock : randomized, placebo-controlled trial. J Antimicrob Chemother. 2005 ; 55 : 90-4.
 
6) O'Horo JC, Silva GL, Safdar N. Anti-infective locks for treatment of central line-associated bloodstream infection : a systematic review and meta-analysis. Am J Nephrol. 2011 ; 34 : 415-22.
 
7) Minejima E, Mai N, Bui N, et al. Defining the breakpoint duration of Staphylococcus aureus bacteremia predictive of poor outcomes. Clin Infect Dis. 2020 ; 70 : 566-73.
PubMed
8) Fernandez-Cruz A, Cruz Menarguez M, Munoz P, et al. The search for endocarditis in patients with candidemia : a systematic recommendation for echocardiography? A prospective cohort. Eur J Clin Microbiol Infect Dis. 2015 ; 34 : 1543-9.
 
9) Holland TL, Arnold C, Fowler VG Jr. Clinical management of Staphylococcus aureus bacteremia : a review. JAMA. 2014 ; 312 : 1330-41.
PubMed
10) Li HK, Rombach I, Zambellas R, et al. Oral versus Intravenous antibiotics for bone and joint infection. N Engl J Med. 2019 ; 380 : 425-36.
PubMed
11) Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2019 ; 380 : 415-24.
PubMed
12) Bupha-Intr O, Blackmore T, Bloomfield M. Efficacy of early oral switch with β-Lactams for low-risk Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2020 ; 64 : e02345-19.
 

[CHAPTER 6] 構造異常

P.116 掲載の参考文献
1) Rolston KV. Infections in cancer patients with solid tumors : a review. Infect Dis Ther. 2017 ; 6 : 69-83.
PubMed
2) 日本呼吸器学会成人肺炎診療ガイドライン2017作成委員会. 成人肺炎診療ガイドライン 2017.
 
3) Abers MS, Sandvall BP, Sampath R, et al. Postobstructive pneumonia : An underdescribed syndrome. Clin Infect Dis. 2016 ; 62 (8) : 957-61.
PubMed
4) Liaw YS, Yang PC, Wu ZG, et al. The bacteriology of obstructive pneumonitis. A prospective study using ultrasound-guided transthoracic needle aspiration. Am J Respir Crit Care Med. 1994 ; 149 : 1648-53.
PubMed
5) Liao WY, Liaw YS, Wang HC, et al. Bacteriology of infected cavitating lung tumor. Am J Respir Crit Care Med. 2000 ; 161 : 1750-3.
PubMed
6) Leung JW, Chan RC, Cheung SW, et al. The effect of obstruction on the biliary excretion of cefoperazone and ceftazidime. J Antimicrob Chemother. 1990 ; 25 : 399-406.
PubMed
7) Leung JW, Chan CY, Lai CW, et al. Effect of biliary obstruction on the hepatic excretion of imipenem-cilastatin. Antimicrob Agents Chemother. 1992 ; 36 : 2057-60.
PubMed
8) Chen HY, Ma XM, Ye M, et al. Esophageal perforation during or after conformal radiotherapy for esophageal carcinoma. J Radiat Res. 2014 ; 55 : 940-7.
PubMed
9) Charbonneau H, Maillet JM, Faron M, et al. Mediastinitis due to Gram-negative bacteria is associated with increased mortality. Clin Microbiol Infect. 2014 ; 20 : O197-202.
PubMed
10) Norder Grusell E, Dahlen G, Ruth M, et al. Bacterial flora of the human oral cavity, and the upper and lower esophagus. Dis Esophagus. 2013 ; 26 : 84-90.
PubMed
11) Brook I, Frazier EH. Microbiology of mediastinitis. Arch Intern Med. 1996 12 ; 156 : 333-6.
 
12) Clifford TG, Katebian B, Van Horn CM, et al. Urinary tract infections following radical cystectomy and urinary diversion : a review of 1133 patients. World J Urol. 2018 ; 36 : 775-781.
PubMed
13) Mano R, Baniel J, Goldberg H, et al. Urinary tract infections in patients with orthotopic neobladder. Urol Oncol. 2014 ; 32 : 50. e9-14.
PubMed
P.119 掲載の参考文献
1) Cormier JN, Askew RL, Mungovan KS, et al. Lymphedema beyond breast cancer : a systematic review and meta-analysis of cancer-related secondary lymphedema. Cancer. 2010 ; 116 : 5138.
PubMed
2) Kuroda K, Yamamoto Y, Yanagisawa M, et al. Risk factors and a prediction model for lower limb lymphedema following lymphadenectomy in gynecologic cancer : a hospital-based retrospective cohort study. BMC Womens Health. 2017 ; 17 : 50.
 
3) Bakar Y, Tugral A. Lower extremity lymphedema management after gynecologic cancer surgery : a review of current management strategies. Ann Vasc Surg. 2017 ; 44 : 442.
PubMed
4) Hayes SC, Janda M, Ward LC, et al. Lymphedema following gynecological cancer : Results from a prospective, longitudinal cohort study on prevalence, incidence and risk factors. Gynecol Oncol 2017 ; 146 : 623.
PubMed
5) Dupuy A, Benchikhi H, Roujeau JC, et al. Risk factors for erysipelas of the leg (cellulitis) : case-control study. BMJ. 1999 ; 318 : 1591-4.
PubMed
6) Tay EY, Fook-Chong S, Oh CC, et al. Cellulitis recurrence score : a tool for predicting recurrence of lower limb cellulitis. J Am Acad Dermatol. 2015 ; 72 : 140-5.
 
7) Firas Al-Niaimi NC. Cellulitis and lymphoedema : a vicious cycle. J Lymphoedema. 2009 ; 4 : 38-42.
 
8) Keeley VM, P, Hughes A, Riches K, Consensus Document on the Management of Cellulitis in Lymphoedema. British Lymphology Society, Cheltenham. Available online at : https://www.lymphoedema.org/images/pdf/CellulitisConsensus.pdf, 2016.
 
9) Baddour LM, Bisno AL. Non-group A beta-hemolytic Streptococcal cellulitis. Association with venous and lymphatic compromise. Am J Med. 1985 ; 79 : 155-9.
 
10) Mortimer PS, Levick JR. Chronic peripheral oedema : the critical role of the lymphatic system. Clin Med. 2004 ; 4 : 448-53.
PubMed
11) Rodriguez JR, Hsieh F, Huang CT, et al. Clinical features, microbiological epidemiology and recommendations for management of cellulitis in extremity lymphedema. J Surg Oncol. 2020 ; 121 : 25-36.
PubMed
12) Swartz MN. Clinical practice. Cellulitis. N Engl J Med. 2004 ; 350 : 904-12.
PubMed
13) Perl B, Gottehrer NP, Raveh D, et al. Cost-effectiveness of blood cultures for adult patients with cellulitis. Clin Infect Dis. 1999 ; 29 : 1483-8.
PubMed
14) Woo PC, Lum PN, Wong SS, et al. Cellulitis complicating lymphoedema. Eur J Clin Microbiol Infect Dis. 2000 ; 19 : 294-7.
 
15) Park SI, Yang EJ, Kim DK, et al. Prevalence and epidemiological factors involved in cellulitis in Korean patients with lymphedema. Ann Rehabil Med. 2016 ; 40 : 326-33.
PubMed
16) Australasian Lymphology Association, Management of cellulitis in lymphoedema. 2015. Available online at : https://www.lymphoedema.org.au/public/7/files/Position%20Statements/ALA%20Consensus%20Guideline%20Cellulitis-Rebrand%202019(1).pdf
 

[CHAPTER 7] がん患者とワクチン

P.128 掲載の参考文献
1) Vollaard A, Schreuder I, Slok-Raijmakers L, et al. Influenza vaccination in adult patients with solid tumours treated with chemotherapy. Eur J Cancer. 2017 ; 76 : 134-43.
PubMed
2) Taha A, Vinograd I, Sakhnini A, et al. The association between infections and chemotherapy interruptions among cancer patients : prospective cohort study. J Infect. 2015 ; 70 : 223-9.
PubMed
3) Tai Y, Lee TC, Chang HL, et al. Epidemiology and outcomes of hospitalization of influenza in the cancer population in Taiwan. J Cancer Res Clin Oncol. 2009 ; 135 : 1061-6.
 
4) Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014 ; 58 : e44-100.
PubMed
5) Anderson H, Petrie K, Berrisford C, et al. Seroconversion after influenza vaccination in patients with lung cancer. Br J Cancer. 1999 ; 80 : 219-20.
PubMed
6) Earle CC. Influenza vaccination in elderly patients with advanced colorectal cancer. J Clin Oncol. 2003 ; 21 : 1161-6.
PubMed
7) Vinograd I, Eliakim-Raz N, Farbman L, et al. Clinical effectiveness of seasonal influenza vaccine among adult cancer patients. Cancer. 2013 ; 119 : 4028-35.
PubMed
8) Lubli H, Balmelli C, Kaufmann L, et al. Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events. J Immunother Cancer. 2018 ; 6 : 40.
 
9) Chong CR, Park VJ, Cohen B, et al. Safety of inactivated influenza vaccine in cancer patients receiving immune checkpoint inhibitors (ICI). Clin Infect Dis. 2019 ; 70 : 193-9.
 
10) Xu Y, Methuku N, Coimbatore P, et al. Immunogenicity of an inactivated monovalent 2009 influenza A (H1N1) vaccine in patients who have cancer. Oncologist. 2012 ; 17 : 125-34.
PubMed
11) Wumkes ML, van der Velden AM, Los M, et al. Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours. Vaccine. 2013 ; 31 : 6177-84.
PubMed
12) Waqar SN, Boehmer L, Morgensztern D, et al. Immunogenicity of influenza vaccination in patients with cancer. Am J Clin Oncol. 2018 ; 41 : 248-53.
PubMed
13) Keam B, Kim MK, Choi SJ, et al. Optimal timing of influenza vaccination during 3-week cytotoxic chemotherapy cycles. Cancer. 2017 ; 123 : 841-8.
PubMed
14) Locher JL, Rucks AC, Spencer SA, et al. Influenza immunization in older adults with and without cancer. J Am Geriatr Soc. 2012 ; 60 : 2099-103.
 
15) Loulergue P, Mir O, Alexandre J, et al. Low influenza vaccination rate among patients receiving chemotherapy for cancer. Ann Oncol. 2008 ; 19 : 1658.
 
16) Siebert JN, Posfay-Barbe KM, Habre W, et al. Influence of anesthesia on immune responses and its effect on vaccination in children : review of evidence. Paediatr Anaesth. 2007 ; 17 : 410-20.
PubMed
17) Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions : recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012 ; 61 : 816-9.
PubMed
18) Briere EC, Rubin L, Moro PL, et al. Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, CDC. Prevention and control of haemophilus influenzae type b disease : recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2014 ; 63 : 1-14.
PubMed
19) Cohn AC, MacNeil JR, Clark TA, et al. Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease : recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013 ; 62 : 1-28.
PubMed

[CHAPTER 8] がんを模倣する感染症

P.140 掲載の参考文献
1) Rolston KV, Rodriguez S, Dholakia N, et al. Pulmonary infections mimicking cancer : a retrospective, three-year review. Support Care Cancer. 1997 ; 5 : 90-3.
 
2) Homrich GK, Andrade CF, Marchiori RC, et al. Prevalence of benign diseases mimicking lung cancer : experience from a university hospital of southern Brazil. Tuberc Respir Dis (Seoul). 2015 ; 78 : 72-7.
PubMed
3) Jensen PA, Lambert LA, Iademarco MF, et al. CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep. 2005 ; 54 : 1-141.
PubMed
4) Bhatt M, Kant S, Bhaskar R. Pulmonary tuberculosis as differential diagnosis of lung cancer. South Asian J Cancer. 2012 ; 1 : 36-42.
PubMed
5) Leung AN. Pulmonary tuberculosis : the essentials. Radiology. 1999 ; 210 : 307-22.
PubMed
6) Im JG, Itoh H, Shim YS, et al. Pulmonary tuberculosis : CT findings-early active disease and sequential change with antituberculous therapy. Radiology. 1993 ; 186 : 653-60.
PubMed
7) Weinberger SE, McDermott S. Diagnostic evaluation of the incidental pulmonary nodule. UpToDate. 2019.
 
8) Ko JM, Park HJ, Kim CH, et al. The relation between CT findings and sputum microbiology studies in active pulmonary tuberculosis. Eur J Radiol. 2015 ; 84 : 2339-44.
PubMed
9) Dodd GD, Boyle JJ. Excavating pulmonary metastases. Am J Roentgenol Radium Ther Nucl Med. 1961 ; 85 : 277-93.
PubMed
10) Seo JB, Im JG, Goo JM, et al. Atypical pulmonary metastasis : spectrum of radiologic findings. Radiographics. 2001 ; 21 : 403-17.
PubMed
11) Onn A, Choe DH, Herbst RS, et al. Tumor cavitation in stage I non-small cell lung cancer : epidermal growth factor receptor expression and prediction of poor outcome. Radiology. 2005 ; 237 : 342-7.
 
12) Balikian JP, Herman PG. Non-Hodgkin lymphoma of the lungs. Radiology. 1979 ; 132 : 569-76.
PubMed
13) Sandler AB, Johnson DH, Brahmer J, et al. A study of clinical and radiographic risk factors associated with early onset severe pulmonary hemorrhage in bevacizumab (Avastin) treated patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol. 2006 ; 24 : 7068.
 
14) Fennessy JJ. Irradiation damage to the lung. J Thoracic Imaging. 1987 ; 2 : 68-79.
 
15) Miller WT, MacGregor RR. Tuberculosis : frequency of unusual radiographic findings. AJR Am J Roentgenol. 1978 ; 130 : 867-75.
PubMed
16) Van Dyck P, Vanhoenacker FM, Van den Brande P, et al. Imaging of pulmonary tuberculosis. Eur Radiol. 2003 ; 13 : 1771-85.
PubMed
17) Lynch DA, Simone PM, Fox MA, et al. CT features of pulmonary Mycobacterium avium complex infection. J Comput Assist Tomogr. 1995 ; 19 : 353-60.
 
18) Conant EF, Wechsler RJ. Actinomycosis and nocardiosis of the lung. J Thorac Imaging. 1992 ; 7 : 75-84.
 
19) Yano S, Usui N, Asai O, et al. Septic intramuscular embolism in a neutropenic patient with myelodysplastic syndrome accompanied by asymptomatic septic pulmonary emboli. Intern Med. 2005 ; 44 : 1100-2.
 
20) Park Y, Kim TS, Yi CA, et al. Pulmonary cavitary mass containing a mural nodule : differential diagnosis between intracavitary aspergilloma and cavitating lung cancer on contrast-enhanced computed tomography. Clin Radiol. 2007 ; 62 : 227-32.
PubMed
21) Chang WC, Tzao C, Hsu HH, et al. Pulmonary cryptococcosis : comparison of clinical and radiographic characteristics in immunocompetent and immunocompromised patients. Chest. 2006 ; 129 : 333-40.
PubMed
22) Sheflin JR, Campbell JA, Thompson GP. Pulmonary blastomycosis : findings on chest radiographs in 63 patients. AJR Am J Roentgenol. 1990 ; 154 : 1177-80.
PubMed
23) Kennedy CC, Limper AH. Redefining the clinical spectrum of chronic pulmonary histoplasmosis : a retrospective case series of 46 patients. Medicine (Baltimore). 2007 ; 86 : 252-8.
PubMed
24) Greendyke WH, Resnick DL, Harvey WC. The varied roentgen manifestations of primary coccidioidomycosis. Am J Roentgenol Radium Ther Nucl Med. 1970 ; 109 : 491-9.
PubMed
25) McAdams HP, Rosado de Christenson M, Strollo DC, et al. Pulmonary mucormycosis : radiologic findings in 32 cases. AJR Am J Roentgenol. 1997 ; 168 : 1541-8.
PubMed
26) Baruch AC, Steinbronn K, Sobonya R. Pulmonary adenocarcinomas associated with rheumatoid nodules : a case report and review of the literature. Arch Pathol Lab Med. 2005 ; 129 : 104-6.
PubMed
27) Kuhlman JE, Hruban RH, Fishman EK. Wegener granulomatosis : CT features of parenchymal lung disease. J Comput Assist Tomogr. 1991 ; 15 : 948-52.
PubMed
28) Lee KS, Kim TS, Fujimoto K, et al. Thoracic manifestation of Wegener's granulomatosis : CT findings in 30 patients. Eur Radiol. 2003 ; 13 : 43-51.
 
29) He H, Stein MW, Zalta B, et al. Pulmonary infarction : spectrum of findings on multidetector helical CT. J Thorac Imaging. 2006 ; 21 : 1-7.
PubMed
30) Cheon JE, Im JG, Kim MY, et al. Thoracic actinomycosis : CT findings. Radiology. 1998 ; 209 : 229-33.
PubMed
31) Kwong JS, Mumller NL, Godwin JD, et al. Thoracic actinomycosis : CT findings in eight patients. Radiology. 1992 ; 183 : 189-92.
 
P.143 掲載の参考文献
1) WHO. Japan-Cancer Country Profile https://www.who.int/cancer/country-profiles/jpn_en.pdf?ua=1
 
2) WHO. Thailand-Cancer Country Profile http://www.who.int/cancer/country-profiles/tha_en.pdf?ua=1
 
3) Vatanasapt V, Sriamporn S, Vatanasapt P. Cancer control in Thailand. Jpn J Clin Oncol. 2002 ; 32 Suppl : S82-S91. doi : 10.1093/jjco/hye134
 
4) Opisthorchiasis. CDC DPDx. https://www.cdc.gov/dpdx/opisthorchiasis/index.html
 
5) Kaewpitoon N, Kaewpitoon SJ, Pengsaa P, et al. Opisthorchis viverrini : the carcinogenic human liver fluke. World J Gastroenterol. 2008 ; 14 (5) : 666-674. doi : 10.3748/wjg.14.666
 
P.145 掲載の参考文献
1) Handa O, Naito Y, Yoshikawa T. Helicobacter pylori : a ROS-inducing bacterial species in the stomach. Inflamm Res. 2010 ; 59 : 997-1003. doi : 10.1007/s00011-010-0245-x
 
2) Abdulamir AS, Hafidh RR, Abu Bakar F. The association of Streptococcus bovis/gallolyticus with colorectal tumors : the nature and the underlying mechanisms of its etiological role. J Exp Clin Cancer Res. 2011 ; 30 (1) : 11.
 
3) Takahashi Y, Ishiwada N, Tanaka J, et al. Streptococcus gallolyticus subsp. pasteurianus meningitis in an infant. Pediatr Int. 2014 ; 56 : 282-285. doi : 10.1111/ped.12254
 
4) Sturt AS, Yang L, Sandhu K, Pei Z, Cassai N, Blaser MJ. Streptococcus gallolyticus subspecies pasteurianus (biotype II/2), a newly reported cause of adult meningitis. J Clin Microbiol. 2010 ; 48 : 2247-9.
PubMed
5) Corredoira J, Alonso MP, Coira A, et al. Association between Streptococcus infantarius (formerly S. bovis II/1) bacteremia and noncolonic cancer. J Clin Microbiol. 2008 ; 46 : 1570.
 
6) Corredoira J, Alonso MP, Garcia-Garrote F, et al. Streptococcus bovis group and biliary tract infections : an analysis of 51 cases. Clin Microbiol Infect. 2014 ; 20 : 405-9.
PubMed
7) Kimura M, Araoka H, Yoneyama A. Aeromonas caviae is the most frequent pathogen amongst cases of Aeromonas bacteremia in Japan. Scand J Infect Dis. 2013 ; 45 : 304-9.
PubMed
8) Duthie R, Ling TW, Cheng AF, et al. Aeromonas septicaemia in Hong Kong species distribution and associated disease. J Infect. 1995 ; 30 : 241-4.
 
9) Janda JM, Guthertz LS, Kokka RP, et al. Aeromonas species in septicemia : laboratory characteristics and clinical observations. Clin Infect Dis. 1994 ; 19 : 77-83.
 
10) Mirza NN, McCloud JM, Cheetham MJ. Clostridium septicum sepsis and colorectal cancer-a reminder. World J Surg Oncol. 2009 ; 7 : 73.
PubMed
11) Kennedy CL, Krejany EO, Young LF, et al. The alpha-toxin of Clostridium septicum is essential for virulence. Mol Microbiol. 2005 ; 57 : 1357-66.
PubMed
12) Larson CM, Bubrick MP, Jacobs DM, West MA. Malignancy, mortality, and medicosurgical management of Clostridium septicum infection. Surgery. 1995 ; 118 : 592-8.
PubMed

[CHAPTER 9] 手術と感染症

P.164 掲載の参考文献
1) Itoh N, Hadano Y, Yamamoto Y. et al. Infectious disease specialist consultations in a Japanese cancer center : a retrospective review of 776 cases. BMC Health Serv Res 20, 500 (2020).
 
2) Laupland KB, Shahpori R, Kirkpatrick AW, et al. Occurrence and outcome of fever in critically ill adults. Crit Care Med. 2008 ; 36 : 1531-5.
PubMed
3) Nadene C. Postoperative Fevers. Hospital Medicine Clinics. 2012 ; 1 : e457-70.
 
4) House J, Alexandraki I. Postoperative fever. BMJ Best Practice 2012.
 
5) Dauleh MI, Rahman S, Townell NH. Open versus laparoscopic cholecystectomy : a comparison of postoperative temperature. J R Coll Surg Edinb. 1995 ; 40 : 116-8.
PubMed
6) Clark JA, Bar-Yosef S, Anderson A, et al. Postoperative hyperthermia following off-pump versus on-pump coronary artery bypass surgery. J Cardiothorac Vasc Anesth. 2005 ; 19 : 426-9.
 
7) O'Grady NP, Barie PS, Bartlett JG, et al. Practice guidelines for evaluating new fever in critically ill adult patients. Task Force of the Society of Critical Care Medicine and the Infectious Diseases Society of America. Clin Infect Dis. 1998 ; 26 : 1042-59.
 
8) Weed HG. Postoperative fever. UpToDate. Nov 25, 2019.
 
9) Bartlett P, Reingold AL, Graham DR, et al. Toxic shock syndrome associated with surgical wound infections. JAMA. 1982 12 ; 247 : 1448-50.
PubMed
10) Takazawa T, Ohta J, Horiuchi T, et al. A case of acute onset postoperative gas gangrene caused by Clostridium perfringens. BMC Res Notes. 2016 ; 9 : 385.
PubMed
11) Bratzler DW, Dellinger EP, Olsen KM, et al. American Society of Health-System Pharmacists ; Infectious Disease Society of America ; Surgical Infection Society ; Society for Healthcare Epidemiology of America. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013 1 ; 70 (3) : 195-283.
 
12) 日本化学療法学会/日本外科感染症学会 術後感染予防抗菌薬適正使用に関するガイドライン作成委員会, 編. 術後感染予防抗菌薬適正使用のための実践ガイドライン. 2016.
 
13) Ban KA, Minei JP, Laronga C, et al. American College of Surgeons and Surgical Infection Society : Surgical Site Infection Guidelines, 2016 Update. J Am Coll Surg. 2017 ; 224 : 59-74.
PubMed
14) Sandra I. Berrios-Torres, Umscheid CA, et al. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. JAMA Surg. 2017 ; 152 (8) : 784-91.
PubMed
15) Global Guidelines for the Prevention of Surgical Site Infection. World Health Organization, 2016. [http://www.who.int/gpsc/ssi-prevention-guidelines/en/]
 
16) CDC. Influenza. https://www.cdc.gov/vaccines/pubs/surv-manual/chpt06-influenza.html
 
17) Lei S, Jiang F, Su W, et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30075-4/fulltext
 
18) Kulhankova K, King J, Salgado-Pabon W. Staphylococcal toxic shock syndrome : superantigen-mediated enhancement of endotoxin shock and adaptive immune suppression. Immunol Res. 2014 ; 59 (1-3) : 182-7.
 
19) Mangram AJ, Horan TC, Pearson ML, et al. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1999 ; 20 : 250-78.
PubMed
20) Anderson DJ, Podgorny K, Berrios-Torres SI, et al. Strategies to prevent surgical site infections in acute care hospitals : 2014 update. Infect Control Hosp Epidemiol, 2014 ; 35 : Suppl 2 : S66-88.
 
21) Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections : 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014 ; 15 : e10-52.
 
22) Hensgens MP, Goorhuis A, Dekkers OM, et al. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother. 2012 ; 67 : 742-8.
PubMed
P.169 掲載の参考文献
1) Sartelli M, Chichom-Mefire A, Labricciosa FM, et al. The management of intra-abdominal infections from a global perspective : 2017 WSES guidelines for management of intra-abdominal infections. World J Emerg Surg. 2017 ; 12 : 29.
PubMed
2) Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection. Surg Infect (Larchmt). 2017 ; 18 : 1-76.
PubMed
3) Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children : guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010 ; 50 (2) : 133-64.
 
4) Takesue Y, Kusachi S, Mikamo H, et al. Antimicrobial susceptibility of common pathogens isolated from postoperative intra-abdominal infections in Japan. J Infect Chemother. 2018 ; 24 : 330-40.
 
5) Hayakawa K, Nagamatsu M, Mezaki K, et al. Epidemiology of extended-spectrum beta-lactamase (ESBL) producing Escherichia coli in Japan : Characteristics of community-associated versus healthcare-associated ESBL E. coli. J Infect Chemother. 2017 ; 23 : 117-119.
PubMed
6) Harris PNA, Tambyah PA, Lye DC, et al. Effect of piperacillin-tazobactam vs meropenem on 30-Day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance : a randomized clinical Trial. MA. 2018 11 ; 320 : 984-94.
 
7) Sharara SL, Amoah J, Pana ZD, et al. Is Piperacillin-Tazobactam effective for the Treatment of pyelonephritis caused by ESBL-producing organisms? Clin Infect Dis. 2019. Clin Infect Dis. 2020 ; 71 (8) : e331-e337.
 
8) Rodriguez-Bano J, Gutierrez-Gutierrez B, Machuca I, et al. Treatment of infections caused by extended-spectrum-beta-lactamase-, ampC-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev. 2018 ; 31 : e00079-17.
PubMed
9) Fukuchi T, Iwata K, Kobayashi S, et al. Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems. BMC Infect Dis. 2016 ; 16 : 427.
PubMed
10) Bamberger DM. Outcome of medical treatment of bacterial abscesses without therapeutic drainage : review of cases reported in the literature. Clin Infect Dis. 1996 ; 23 : 592-603.
PubMed

[CHAPTER 10] 腫瘍熱

P.180 掲載の参考文献
1) Toussaint E, Bahel-Ball E, Vekemans M, et al. Causes of fever in cancer patients (prospective study over 477 episodes). Support Care Cancer. 2006 ; 14 : 763-9.
PubMed
2) Zell JA, Chang JC. Neoplastic fever : a neglected paraneoplastic syndrome. Support Care Cancer 2005 ; 13 : 870-7.
 
3) Chang JC. Neoplastic fever. A proposal for diagnosis. Arch Intern Med. 1989 ; 149 : 1728-30.
 
4) Zhang H, Wu Y, Lin Z, et al. Naproxen for the treatment of neoplastic fever : A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2019 ; 98 : e15840.
 
5) Liaw CC, Huang JS, Chen JS, et al. Using vital sign flow sheets can help to identify neoplastic fever and other possible causes in oncology patients : a retrospective observational study. J Pain Symptom Manage. 2010 ; 40 : 256-65.
PubMed
6) Kallio R, Bloigu A, Surcel HM, et al. C-reactive protein and erythrocyte sedimentation rate in differential diagnosis between infections and neoplastic fever in patients with solid tumours and lymphomas. Support Care Cancer. 2001 ; 9 (2) : 124-8.
PubMed
7) Shomali W, Hachem R, Chaftari AM, et al. Can procalcitonin distinguish infectious fever from tumor-related fever in non-neutropenic cancer patients? Cancer. 2012 ; 118 : 5823-9.
PubMed
8) Penel N, Fournier C, Clisant S, et al. Causes of fever and value of C-reactive protein and procalcitonin in differentiating infections from paraneoplastic fever. Support Care Cancer. 2004 ; 12 : 593-8.
PubMed
9) Chang JC, Gross HM. Utility of naproxen in the differential diagnosis of fever of undetermined origin in patients with cancer. Am J Med. 1984 ; 76 : 597-603.
PubMed
10) Chang JC. How to differentiate neoplastic fever from infectious fever in patients with cancer : usefulness of the naproxen test. Heart Lung. 1987 ; 16 : 122-7.
PubMed
11) Zhang H, Wu Y, Lin Z, et al. Naproxen for the treatment of neoplastic fever : A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2019 ; 98 : e15840.
 
12) Pasikhova Y, Ludlow S, Baluch A. Fever in Patients With Cancer. Cancer Control. 2017 ; 24 : 193-197.
PubMed
P.184 掲載の参考文献
1) Toussaint E, Bahel-Ball E, Vekemans M, et al. Causes of fever in cancer patients (prospective study over 477 episodes). Support Care Cancer. 2006 ; 14 : 763-9.
PubMed
2) Patel RA, Gallagher JC. Drug fever. Pharmacotherapy. 2010 ; 30 : 57-69.
PubMed
3) Mackowiak PA, LeMaistre CF. Drug fever : a critical appraisal of conventional concepts. An analysis of 51 episodes in two Dallas hospitals and 97 episodes reported in the English literature. Ann Intern Med. 1987 ; 106 : 728-33.
 
4) Johnson DH, Cunha BA. Drug fever. Infect Dis Clin North Am. 1996 ; 10 : 85-91.
PubMed
5) Cunha BA. The diagnostic significance of relative bradycardia in infectious disease. Clin Microbiol Infect. 2000 ; 6 : 633-4.
PubMed
6) Lipsky BA, Hirschmann JV. Drug fever. JAMA. 1981 ; 245 : 851-4.
PubMed
7) Tabor PA. Drug-induced fever. Drug Intell Clin Pharm. 1986 ; 20 : 413-20.
PubMed
8) Oizumi K, Onuma K, Watanabe A, et al. Clinical study of drug fever induced by parenteral administration of antibiotics. Tohoku J Exp Med. 1989 ; 159 : 45-56.
PubMed
9) Pasikhova Y, Ludlow S, Baluch A. Fever in patients with cancer. Cancer Control. 2017 ; 24 : 193-197.
PubMed
10) Li GN, Wang SP, Xue X, et al. Monoclonal antibody-related drugs for cancer therapy. Drug Discov Ther. 2013 ; 7 : 178-184.
PubMed
11) Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006 ; 17 : 897-907.
PubMed
12) Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer : 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011 ; 52 : e56-e93.
 

[CHAPTER 11] 新規がん薬物療法と感染症

P.198 掲載の参考文献
1) NCCN Guidelines ver2. 2020 Prevention and Treatment of Cancer-Related Infections. https://www.nccn.org/professionals/physician_gls/default.aspx
 
2) Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018 ; 378 (2) : 158-68.
PubMed
3) Khoja L, Day D, Wei-Wu Chen T, el al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors : a systematic review. Ann Oncol. 2017 ; 28 : 2377-2385.
 
4) Kyi C, Hellmann MD, Wolchok JD, el al. Opportunistic infections in patients treated with immunotherapy for cancer. J Immunother Cancer. 2014 ; 2 : 19.
 
5) Uslu U, Agaimy A, Hundorfean G, el al. Autoimmune colitis and subsequent CMV-induced hepatitis after treatment With Ipilimumab. J Immunother. 2015 ; 38 : 212-5.
 
6) Arriola E, Wheater M, Krishnan R, el al. Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control. Oncoimmunology. 2015 ; 4 : e1040218.
 
7) 造血細胞移植ガイドライン サイトメガロウイルス感染症 第3版. https://www.jshct.com/uploads/files/guideline/01_03_01cmv04
 
8) Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab : a meta-analysis. Lancet Oncol. 2009 ; 10 : 559-68.
PubMed
9) Cortes J, Caralt M, Delaloge S, et al. Safety of bevacizumab in metastatic breast cancer patients undergoing surgery. Eur J Cancer. 2012 ; 48 : 475-81.
PubMed
P.203 掲載の参考文献
1) Perez-Jacoiste Asin MA, Fernandez-Ruiz M, Lopez-Medrano F, et al. Bacillus Calmette-Guerin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer : incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine (Baltimore). 2014 ; 93 : 236-254.
 
2) Green DB, Kawashima A, Menias CO, et al. Complications of Intravesical BCG Immunotherapy for bladder cancer. Radiographics. 2019 ; 39 (1) : 80-94.
PubMed
3) Marques M, Vazquez D, Sousa S, et al. Disseminated Bacillus Calmette-Guerin (BCG) infection with pulmonary and renal involvement : A rare complication of BCG immunotherapy. A case report and narrative review [published online ahead of print, 2019 Nov 8]. Pulmonology. 2019 ; S2531-0437 (19) : 30181-3.
 
4) Gandhi NM, Morales A, Lamm DL. Bacillus Calmette-Guerin immunotherapy for genitourinary cancer. BJU Int. 2013 ; 112 : 288-297.
PubMed
5) Larsen ES, Nordholm AC, Lillebaek T, et al. The epidemiology of bacille Calmette-Guerin infections after bladder instillation from 2002 through 2017 : a nationwide retrospective cohort study. BJU Int. 2019 ; 124 : 910-916.
PubMed
6) Lamm DL, van der Meijden PM, Morales A, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol. 1992 ; 147 : 596-600.
PubMed
7) Gonzalez OY, Musher DM, Brar I, et al. Spectrum of bacille Calmette-Guerin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis. 2003 ; 36 : 140-148.
PubMed

[CHAPTER 12] 放射線治療と感染症

P.215 掲載の参考文献
1) Leech M, Katz MS, Kazmierska J, et al. Empowering patients in decision-making in radiation oncology-can we do better?. Mol Oncol. 2020 ; 14 : 1442-60.
PubMed
2) Berkey FJ. Managing the adverse effects of radiation therapy. Am Fam Physician. 2010 ; 82 : 381-94.
PubMed
3) 放射線治療計画ガイドライン 2016. https://www.jastro.or.jp/medicalpersonnel/guideline/jastro/2016.html
 
4) Lerman MA, Laudenbach J, Marty FM, et al. Management of oral infections in cancer patients. Dent Clin North Am. 2008 ; 52 : 129-53.
PubMed
5) Brook I. Acute bacterial suppurative parotitis : microbiology and management. J Craniofac Surg. 2003 ; 14 : 37-40.
PubMed
6) Raad II, Sabbagh MF, Caranasos GJ. Acute bacterial sialadenitis : a study of 29 cases and review. Rev Infect Dis. 1990 ; 12 : 591-601.
PubMed
7) Cheng MP, Abou Chakra CN, Yansouni CP, et al. Risk of active tuberculosis in patients with cancer : a systematic review and meta-analysis. Clin Infect Dis. 2017 ; 64 : 635-44.
 
8) Akinosoglou KS, Karkoulias K, and Marangos M, Infectious complications in patients with lung cancer. Eur Rev Med Pharmacol Sci, 2013 ; 17 : 8-18.
PubMed
9) Xu B, Boero IJ, Hwang L, et al. Aspiration pneumonia after concurrent chemoradiotherapy for head and neck cancer. Cancer. 2015 ; 121 : 1303-11.
PubMed
10) Jimmy J. Caudell, Philip E. et al. Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009 ; 73 : 410-5.
 
11) Shin US, Kim CW, Yu CS, et al. Delayed anastomotic leakage following sphincter-preserving surgery for rectal cancer. Int J Colorectal Dis. 2010 ; 25 : 843-9.
PubMed
P.218 掲載の参考文献
1) Marik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med. 2001 ; 344 : 665-71.
PubMed
2) Mandell LA, Niederman MS. Aspiration Pneumonia. N Engl J Med. 2019 ; 380 : 651-63.
PubMed
3) Dragan V, Wei Y, Elligsen M, et al. Prophylactic antimicrobial therapy for acute aspiration pneumonitis. Clin Infect Dis. 2018.
PubMed
4) 医療・介護関連肺炎診療ガイドライン 2013.
 
5) El-Solh AA, Pietrantoni C, Bhat A, et al. Microbiology of severe aspiration pneumonia in institutionalized elderly. Am J Respir Crit Care Med. 2003 ; 167 : 1650-4.
PubMed
6) Ishida T, Tachibana H, Ito A, et al. Clinical characteristics of nursing and healthcare-associated pneumonia : a Japanese variant of healthcare-associated pneumonia. Intern Med. 2012 ; 51 : 2537-44.
PubMed
7) Teramoto S, Fukuchi Y, Sasaki H, et al. High incidence of aspiration pneumonia in community- and hospital-acquired pneumonia in hospitalized patients : a multicenter, prospective study in Japan. J Am Geriatr Soc. 2008 ; 56 : 577-9.
PubMed

[CHAPTER 13] 終末期のがん患者と感染症

P.228 掲載の参考文献
1) Macedo F, Nunes C, Ladeira K, et al. Antimicrobial therapy in palliative care : an overview. Support Care Cancer. 2018 ; 26 : 1361-7.
PubMed
2) Thompson AJ, Silveira MJ, Vitale CA, et al. Antimicrobial use at the end of life among hospitalized patients with advanced cancer. Am J Hosp Palliat Care. 2012 ; 29 : 599-603.
PubMed
3) Homsi J, Walsh D, Panta R, et al. Infectious complications of advanced cancer. Support Care Cancer. 2000 ; 8 : 487-92.
PubMed
4) Pereira J, Watanabe S, Wolch G. A retrospective review of the frequency of infections and patterns of antibiotic utilization on a palliative care unit. J Pain Symptom Manag. 1998 ; 16 : 374-81.
 
5) Lagman R, Panta R, Walsh D. Infectious complications in advanced cancer. Support Care Cancer. 1996 ; 4 : 226.
 
6) White PH, Kuhlenschmidt HL, Vancura BG, et al. Antimicrobial use in patients with advanced cancer receiving hospice care. J Pain Symptom Manage. 2003 ; 25 : 438-443.
PubMed
7) Green K, Webster H, Watanabe S, et al. Management of nosocomial respiratory tract infections in terminally-ill cancer patients J Palliat Care. 1994 ; 10 : 31-4.
PubMed
8) Marcus EL, Clarfield AM, Moses AE. Ethical issues relating to the use of antimicrobial therapy in older adults. Clin Infect Dis. 2001 ; 33 : 1697-705.
 
9) Lam PT, Chan KS, Tse CY, et al. Retrospective analysis of antibiotic use and survival in advanced cancer patients with infections. J Pain Symptom Manage. 2005 ; 30 : 536-43.
PubMed
10) Oh DY, Kim JH, Kim DW, et al. Antibiotic use during the last days of life in cancer patients. Eur J Cancer Care. 2006 ; 15 : 74-9.
 
11) Al-Shaqi MA, Hasan Alami A, Al- Zahrani AS, et al. The pattern of antimicrobial use for palliative care in-patients during the last week of life. Am J Hosp Palliat Care. 2011.
 
12) Beckers M, Ruven H, Seldenrijk C et al. Risk of thrombosis and infections of central venous catheters and totally implanted access ports in patients treated for cancer. Thromb Res. 2010 ; 125 : 318-21.
PubMed
13) Narducci F, Jean-Laurent M, Boulanger L et al. Totally implantable venous access port systems and risk factors for complications : a one-year prospective study in a cancer centre. Eur J Surg Oncol. 2011 ; 37 : 913-8.
 
14) Becton D, Kletzel M, Golladay E et al. An experience with an implanted port system in 66 children with cancer. Cancer. 1988 ; 61 : 376-8.
PubMed
15) Winters V, Peters B, Coila S, et al. A trial with a new peripheral implanted vascular access device. Oncol Nurs Forum. 1990 ; 17 : 891-6.
PubMed
16) McNelis J, Zarcone J, Marini C, et al. Outcome of subcutaneously implanted catheters in a teaching hospital. Am J Med Qual. 2002 ; 17 : 185-8.
 
17) Robinson G, Tegtmeier B, Zaia J. Brief report : nosocomial infection rates in a cancer treatment center. Infect Control. 1984 ; 5 : 289-94.
 
18) Rotstein C, Cummings K, Nicolaou A, et al. Nosocomial infection rates at an oncology center. Infect Control Hosp Epidemiol. 1988 ; 9 : 13-9.
PubMed
19) High KP, Bradley SF, Gravenstein S, et al. Clinical practice guideline for the evaluation of fever and infection in older adult residents of long-term care facilities : 2008 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009 ; 48 : 149-71.
 
20) Brooks S, Warshaw G, Hasse L, Kues JR. The physician decision-making process in transferring nursing home patients to the hospital. Arch Intern Med. 1994 ; 154 : 902-8.
 
21) Mehr DR, Binder EF, Kruse RL, et al. Clinical findings associated with radiographic pneumonia in nursing home residents. J Fam Pract. 2001 ; 50 : 931-7.
PubMed
22) Bentley D, Bradley S, High K, et al. Practice guideline for evaluation of fever and infection in long-term care facilities. J Am Geriatr Soc. 2001 ; 49 : 210-22.
PubMed
23) Levin PD, Simor AE, Moses AE, et al. End-of-life treatment and bacterial antibiotic resistance : a potential association. Chest. 2010 ; 138 : 588-94.
PubMed
24) Reinbolt RE, Shenk AM, White PH, et al. Symptomatic treatment of infections in patients with advanced cancer receiving hospice care. J Pain Symptom Manage. 2005 ; 30 : 175-82.
PubMed
25) Clayton J, Fardell B, Hutton-Potts J, et al. Parenteral antibiotics in a palliative care unit : prospective analysis of current practice. Palliat Med. 2003 ; 17 : 44-8.
 
26) Mohammed AA, Al-Zahrani AS, Sherisher MA, et al. The pattern of infection and antibiotics use in terminal cancer patients. J Egypt Natl Canc Inst. 2014 ; 26 : 147-52.
PubMed
27) Morioka S, Mori M, Suzuki T, et al. Determinants of physicians' attitudes toward the management of infectious diseases in terminally-ill patients with cancer [published online ahead of print, 2020 Jul 4]. J Pain Symptom Manage. 2020 ; S0885-3924 (20) 30586-8.
 
28) Stiel S, Krumm N, Pestinger M, et al. Antibiotics in palliative medicine-results from a prospective epidemiological investigation from the HOPE survey. Support Care Cancer. 2012 ; 20 : 325-33.
PubMed

書評

最近チェックした商品履歴

Loading...